rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PHIO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Phio Pharmaceuticals director David Deming buys $10,066 in stock
      Nov 14Investing.comPHIO
      Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
      Nov 12Yahoo FinancePHIO
      Phio Pharmaceuticals director ronald plott acquires $15,189 in shares
      Nov 10Investing.comPHIO
      Phio Pharmaceuticals CEO Robert Bitterman buys $20,500 in stock
      Nov 10Investing.comPHIO
      Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
      Nov 9Yahoo FinancePHIO
      Phio Pharmaceuticals to present Phase 1b trial data at SITC
      Nov 6Investing.comPHIO
      Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
      Nov 6Yahoo FinancePHIO
      Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
      Nov 5Yahoo FinancePHIO
      Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
      Oct 19Yahoo FinancePHIO
      Phio Pharmaceuticals completes first commercial-scale PH-762 batch
      Oct 13Investing.comPHIO
      Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
      Oct 13Yahoo FinancePHIO
      Phio Pharmaceuticals at Small Cap Growth Hybrid Investor Conference: cSCC push By Investing.com
      Oct 8Investing.comPHIO
      Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

      Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio's INTASYL® siRNA...

      Oct 6Yahoo FinancePHIO
      Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

      Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that it has accepted the invitation to present at the National Investment Banking...

      Oct 5Yahoo FinancePHIO
      Phio Pharmaceuticals Expands Equity Incentive Pool at Meeting

      Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailPHIO
      Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

      Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the..

      Sep 23Yahoo FinancePHIO
      Phio Announces Key PH-762 Milestone with FDA Submission for Next Stage of Cutaneous Squamous Cell Carcino
      Sep 14BenzingaPHIO
      Phio Pharmaceuticals submits FDA briefing for PH-762 study
      Sep 14Investing.comPHIO
      Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

      Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and...

      Sep 14Yahoo FinancePHIO
      Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

      Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th.

      Sep 11Yahoo FinancePHIO

      This is the newest page. Registered accounts read further back.